2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.Peer-Reviewed Original ResearchConceptsDisease-free survivalTreatment-related mortalityKarnofsky performance statusT-cell depletionVivo T-cell depletionAllogeneic hematopoietic cell transplantationInferior disease-free survivalHematopoietic cell transplantationOverall survivalT-cell prolymphocytic leukemiaT-PLLPerformance statusInternational BloodCell transplantationProlymphocytic leukemiaLong-term disease-free survivalMarrow Transplant Research databasePoor long-term survivalOutcomes of alloHCTPart of conditioningPost-transplantation relapseSuboptimal performance statusMyeloablative conditioning regimenReduced-intensity conditioningInferior overall survival
2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2020, 34: 3338-3347. PMID: 32313109, PMCID: PMC7572530, DOI: 10.1038/s41375-020-0830-0.Peer-Reviewed Original ResearchConceptsPrimary plasma cell leukemiaHematopoietic cell transplantationKarnofsky performance statusPlasma cell leukemiaAllo-HCTPPCL patientsCell leukemiaNovel agent eraGood partial responseOutcomes of patientsHigh relapse rateAgent eraHCT utilizationSuperior OSPartial responsePerformance statusInferior survivalMedian ageRelapse rateCell transplantationSEER dataMortality 7Multi-variate analysisPatientsSurvival 17